Creating value through strategic investments in early-stage innovative cutting-edge programs and technologies

Business Models

PRIMARY: Create, Incubate & Expand U.S. Start-ups

Interests in innovative preclinical programs
- Cutting-edge/breakthrough technology platforms
- Novel biology/pathway/targets

Prefer platform and pipeline portfolio opportunities than single assets
Open to all stages of preclinical projects but prefer those that already have a lead(s) with 1-3 years before entering clinic

ALTERNATIVE: License-in & JV

Single asset programs – license in for China or global rights
- Global Rights: open to all stages of preclinical and/or early clinical projects
- China Rights: programs that have PoC in clinic
Consider JV for technology platforms

OUR BUSINESS MODEL

(for newco)

DEAL SOURCE

FUTURE OPTIONS

ADVANTAGES
Access to Fosun Pharma Resources:

Business & Operations
Wide Range R&D Resources & Expertise
Shared Facility & Office Space

Primary Areas of Investment

Therapeutic Areas Examples

CNS
Autoimmune disease
Respiratory disease
Metabolic disease
Infectious disease
Cancer (esp. lung, stomach, liver, esophagus）
Rare disease

Technologies Examples

Gene therapy
Nucleic acids/RNA therapeutics
Microbiome
Cell therapy
ProTAC
Vaccines
Small & large molecules

What FUSION Offers

FUNDING

Enhanced seed”/series-A funding for newco

EXPERIENCE

Broad and extensive R&D experience in discovery, preclinical and clinical development
Experience in large pharma and start-up companies in US
Interim executive leadership where needed

RESOURCES

Business functions (BD, legal/IP, finance, HR) shared with Fosun Pharma USA
Shared facility & office space
Operational and program management
Scientific committee / Network of KOLs

ACCESS TO A WIDE RANGE OF RESOURCES THROUGH FOSUN PHARMA

Partnership with Fosun Pharma portfolio company technology platforms (small molecules, mAb, CAR-T, stem cells, etc.)
Clinical development, regulatory and registration team
Manufacturing network (incl. large and small molecules, cell therapy, etc.)
Integrated healthcare system including diagnostics, medical device, hospital and clinic network
Distribution capabilities and market depth (largest private stake holder of Sinopharm Group) in China

Interested?